Wolverine Asset Management’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Wolverine Asset Management’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$9K	–	2521
2022 Q3	$9K	Hold	1,000	–	–	﹤0.01%	2031
2022 Q2	$9K	Hold	1,000	–	–	﹤0.01%	2027
2022 Q1	$9K	Buy	+1,000	New	+$9.81K	﹤0.01%	1930

Other funds holding ORIAU

JNE Partners London, United Kingdom $243M AUM 2.37% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

GAM

Gritstone Asset Management Bethesda, Maryland $104M AUM 6.03% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wolverine Asset Management's ORIAU Position: Q4 2022 in Review

Wolverine Asset Management sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q4 2022, closing a stake of 1,000 shares — an estimated $9K sold.

Wolverine Asset Management first reported a position in ORIAU in Q1 2022 and held it in 3 quarters. The position peaked at $9K in Q3 2022. 6 funds tracked by Wall St. Rank hold ORIAU as of Q4 2022.

Wolverine Asset Management reported no remaining Orion Biotech Opportunities Corp. Units position as of Q4 2022 after selling out during the quarter.
Wolverine Asset Management sold 1,000 Orion Biotech Opportunities Corp. Units shares in Q4 2022, an estimated $9K.
Wolverine Asset Management first reported a position in Orion Biotech Opportunities Corp. Units in Q1 2022 and held it in 3 quarters.
Wolverine Asset Management's Orion Biotech Opportunities Corp. Units position peaked at $9K in Q3 2022.
6 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q4 2022.

Based on Wolverine Asset Management's 13F filing for Q4 2022, filed 1 Feb 2023.